Q/C TECHNOLOGIES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Q/C TECHNOLOGIES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $3.35M | Jul 13, 2018 |
| FY2017 | Dec 31, 2016 | $2.96M | Jul 13, 2018 |
| FY2016 | Dec 31, 2015 | $2.12M | Apr 11, 2017 |
| FY2015 | Dec 31, 2014 | $4.43M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $3.58M | Mar 23, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $1.58M | Mar 25, 2020 |
| FY2019 | Dec 31, 2018 | $1.67M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $3.35M | Apr 1, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $478.7K | Mar 25, 2020 |
| FY2019 | Dec 31, 2018 | $127.3K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $948.6K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.88M | Jul 13, 2018 |
| FY2016 | Dec 31, 2015 | $1.16M | Apr 11, 2017 |
| FY2015 | Dec 31, 2014 | $3.25M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $1.66M | Mar 23, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.63M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($23.36M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($4.00M) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($15.20M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($29.89M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($9.49M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.89M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($10.85M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($7.37M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($3.30M) | Jul 13, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.85M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($10.17M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($17.12M) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($15.28M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($28.81M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($9.49M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.47M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($10.06M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($6.61M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($3.33M) | Jul 13, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.47M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.44M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $7.87M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $9.07M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $6.75M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $2.47M | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | $276.8K | Mar 25, 2020 |
| FY2019 | Dec 31, 2018 | $1.06M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.26M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.19M | Jul 13, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.07M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($8.98M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($12.98M) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($12.27M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($19.52M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($4.66M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.07M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($8.50M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($5.08M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($4.17M) | Jul 13, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2018 | $68.2K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $54.5K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $123.3K | Jul 13, 2018 |
| FY2016 | Dec 31, 2015 | $113.0K | Apr 11, 2017 |
| FY2015 | Dec 31, 2014 | $25.0K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $123.1K | Mar 23, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.17M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $21.42M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $17.86M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $17.54M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $24.81M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $676.7K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $10.88M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $7.81M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $9.34M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $5.09M | Jul 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.44M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $6.70M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $5.09M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $2.84M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.17M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.93M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.53M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $1.97M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.79M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.70M | Jul 13, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.75M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $9.79M | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $12.37M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $14.70M | Apr 11, 2025 |
| FY2023 | Dec 31, 2021 | $23.65M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | ($5.26M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($2.33M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $5.83M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $7.55M | Mar 25, 2020 |
| FY2018 | Dec 31, 2016 | $3.39M | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.50M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $10.50M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $10.50M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $10.50M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $10.50M | Mar 31, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($144.12M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($129.14M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($101.98M) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | ($93.76M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($78.56M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($48.67M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($119.58M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($115.69M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($104.85M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($97.48M) | Jul 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $987.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $173.2K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.68M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | $749.1K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $556.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $148.3K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $517.4K | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $181.8K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $438.4K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $72.7K | Jul 13, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (1,080) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | (11) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (1,080) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | (11) | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7.69M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 33,636 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 2.02M | Apr 11, 2025 |
| FY2023 | Dec 31, 2022 | 1.32M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 37.67M | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | 17.59M | Mar 1, 2021 |
| FY2020 | Dec 31, 2019 | 1.74M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 540,607 | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | 5.53M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 5.45M | Jul 13, 2018 |